A New System Of Care Panel | Founders From One Kidney, Liora Neurotech, Nutromics

Описание: Cicada x Tech23: Australia’s biggest deep tech event
As the biggest deep tech event in the country, Cicada x Tech23 is not just a showcase but a movement. A movement to champion 23 visionary founders, connect them with the right people, and accelerate their journey from lab to market, from startup to scale.

The 2025 Tech23 cohort is tackling challenges from cancer diagnostics and green steel to synthetic biology, precision agriculture, and quantum satellite navigation. These ventures represent the best of Australian deep tech: bold ideas backed by world-class science, and a mission to build a more sustainable, secure, and sovereign future.
________________________________________________________________________________________________
About One Kidney
Over 850 million people are affected globally, with kidney disease costing the Australian health system more than $9 billion each year, according to the International Society of Nephrology
(ISN). However, many die because donor kidneys are scarce and dialysis remains a gruelling, time-consuming treatment. One Kidney is solving this issue with a fully implantable artificial kidney to restore natural function, with no machines and no donor waitlists. The company’s bioinspired membrane system was born after founder Alur Saguinsin witnessed her father’s struggle with kidney failure. This technology, which began as a high-efficiency external dialyser now in clinical validation, is poised to bring the next generation of renal care to life, saving countless lives worldwide.
________________________________________________________________________________________________
About Liora Neurotech
Psychiatric relapse can escalate rapidly, often without sufficient early warning, leading to significant personal and healthcare burdens. Liora Neurotech is addressing this critical issue by developing ‘Lumara’, a wearable biosensor that continuously tracks key biomarkers. Lumara monitors indicators like cortisol, inflammation and melatonin to detect early relapse risk in schizophrenia and bipolar disorder. By enabling continuous sensing, Lumara empowers both patients and clinicians to take proactive steps much earlier, fundamentally shifting mental healthcare from a reactive, crisis-driven model to a preventative and proactive approach, improving outcomes and quality of life for patients worldwide.
________________________________________________________________________________________________
About Nutromics
Traditional lab diagnostics offer only a single, delayed data point, which is insufficient for fast-moving medical conditions. Nutromics is revolutionising diagnostics by providing continuous, real-time biomolecular monitoring. Their lab-on-a-patch technology uses microneedles and DNA-based biosensors to continuously track biomolecules directly at the bedside. This innovation replaces delayed lab data with minute-by-minute visibility, enabling ICU teams to precisely track a patient’s response to treatment. Already tested in humans and backed by $20 million in funding, Nutromics is the first clinically ready system to deliver continuous, real-time diagnostic insights on critical molecular targets, starting with vancomycin (administered IV antibiotic), dramatically improving patient care globally.
________________________________________________________________________________________________
Learn more about Cicada x Tech23
https://www.cicadainnovations.com/cic...

Learn more about One Kidney
https://onekidney.com.au/

Learn more about Liora Neurotech
https://www.liora.health/

Learn more about Nutromics
https://www.nutromics.com/

And a massive shout-out to our ecosystem! To our sponsors, Main Sequence Ventures, Westpac, University of Sydney, Addisons, CFO Plus, CSIRO, Boson Ventures, Dassault Systèmes, IP Australia, Honda Xcelerator Ventures, The Onset, Radium Capital, Techvisa, University of Technology Sydney and City of Sydney, for supporting Tech23.